We can then also bring up BIT that didint meet their endpoint and triggered a 1000% increase by praising a secondary endpoint that has no validated clinical relevance.
I guess the conclusion is that the market is a beast that doesnt work on rationale decision making and hardly understands the science behind many clinical trial outcomes. Of course you cant blame them for that. you have to rely on truthful reporting and scientific integrity regardless of how well you understand the science anyway.
Ann: PAR Reports Successful Phase 2 Clinical Trial, page-34
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.080(16.2%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 58.0¢ | 50.0¢ | $753.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3168 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 102000 | 2 |
View Market Depth
| Last trade - 12.31pm 04/12/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
